News
10-18-2010, 01:30 AM
Celgene Corporation today announced it has completed its acquisition of Abraxis BioScience, Inc. For each share of Abraxis common stock, Abraxis shareholders will receive (i) $58.00 in cash (ii) 0.2617 shares of Celgene common stock, and (iii) one tradeable Contingent Value Right (CVR), which entitles its holder to receive a pro rata share of potential payments for future regulatory milestones and commercial royalties.
More... (http://www.news-medical.net/news/20101018/Celgene-acquires-Abraxis-BioScience.aspx)
More... (http://www.news-medical.net/news/20101018/Celgene-acquires-Abraxis-BioScience.aspx)